0A8E Stock Chart & Stats
$8.46
-$0.28(-3.33%)
At close: 4:00 PM EDT
$8.46
-$0.28(-3.33%)
Day’s Range― - ―
52-Week Range$5.26 - $11.80
Previous CloseN/A
Volume1.46K
Average Volume (3M)4.92K
Market Cap
$1.95B
Enterprise Value$1.54B
Total Cash (Recent Filing)$121.75M
Total Debt (Recent Filing)$289.44M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 05, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding182,320,310
10 Day Avg. Volume5,641
30 Day Avg. Volume4,917
Financial Highlights & Ratios
PEG Ratio-22.22
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue4.58
Enterprise Value/Gross Profit5.50
Enterprise Value/Ebitda92.62
Forecast
1Y Price Target
$13.00Price Target Upside53.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$387.90M
Bulls Say, Bears Say
Bulls Say
Strong Commercial GrowthBroad-based product growth and higher full-year guidance indicate improving commercial execution across Xeris’s portfolio. Recorlev’s rapid expansion, alongside recovery in Gvoke and durable Keveyis demand, can support sustained revenue scaling over the next several quarters.
High-margin Cash GenerationStrong gross profitability and positive free cash flow provide internal funding for commercial expansion, research, and debt reduction. The improvement from prior negative cash flow periods strengthens financial self-sufficiency, although continued execution is needed to sustain these gains.
Protected Specialty PortfolioLong-dated intellectual-property protection can preserve Keveyis’s position in its ultra-rare disease market and support revenue durability. Active enforcement further signals that Xeris is defending product economics and limiting the impact of competing generic products.
Bears Say
Fragile Balance SheetHigh debt relative to a negative equity cushion increases financial risk and limits flexibility if operating performance weakens. Leverage can also constrain investment choices and make the company more dependent on sustained cash generation to fund operations and growth.
Profitability Remains IncompletePositive operating profit has not yet translated into consistent bottom-line earnings, leaving the business exposed to financing, accounting, and investment costs. Persistent net losses could reduce retained capital and make future growth less self-funded if margins do not improve.
Higher Investment BurdenThe planned increase in selling, general, and research spending may accelerate market access and pipeline development, but it raises the earnings hurdle. If revenue growth or XP-8121 progress falls short, elevated costs could delay durable profitability and pressure cash conversion.
Xeris Pharmaceuticals News
0A8E FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest share price was $5.26 and its highest was $11.80 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $1.95B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.192.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.03.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 182,320,310 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went down -12.329%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0A8E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xeris Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (53.66% Upside)
$13.00 (53.66% Upside)
Blogger Sentiment
Bullish
GB:0A8E Sentiment 89%
Sector Average 64%
Sector Average 64%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.29%
12-Months-Change
Fundamentals
Return on Equity
-426.33%
Trailing 12-Months
Asset Growth
23.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
0A8E Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum (notably Recorlev’s 81% YoY growth), improved profitability (86% gross margin, adjusted EBITDA +50% YoY), strategic wins (Keveyis patent protection, retirement of convertible notes) and material pipeline progress for XP-8121 (multiple patents, Phase III planned by year-end). Lowlights were largely manageable: a one-time non-cash GAAP charge of ~$31M, higher near-term SG&A and R&D investments to fund growth and XP-8121, earlier-year softness in Gvoke that has since rebounded, and some remaining timing/enrollment uncertainty around Phase III. Overall, positive commercial execution and balance sheet actions outweigh the near-term charges and increased investment cadence.View all GB:0A8E earnings summaries0A8E Stock 12 Month Forecast
Average Price Target
$13.00
▲(53.66% Upside)